INTRODUCTION
The capacity of the adaptive immune system to spontaneously recognize and respond to tumors is now generally accepted (1, 2) , although these responses are often counteracted by a variety of local immune-inhibitory mechanisms, including signaling through T cell inhibitory receptors (3), such as PD-1. In fact, the therapeutic inhibition of these receptors with antibodies, known as checkpoint inhibitors, can elicit remarkable clinical responses, especially in melanoma and non-small cell lung cancer (4, 5) .
However, for many tumor types, only a minority of patients experiences a therapeutic benefit, a phenomenon ascribed to variations in the tumor microenvironment as well as the magnitude of the local immune response prior to treatment (6, 7) . Thus, it is important to understand how variations in gene expression by tumor cells and the tumor microenvironment contribute to clinical outcomes.
The expression of major histocompatibility class II (MHCII) molecules by tumor cells is one variable that strongly predicts clinical outcomes. Although the expression of MHCII is normally restricted to professional antigen-presenting cells, such as dendritic cells, macrophages and B cells, our group and others have shown that aberrant expression of MHCII pathway components on melanoma (8) , colorectal carcinoma (9, 10), Hodgkin's lymphoma (11) , diffuse large B cell lymphoma (12) , ovarian cancer (13) , and breast cancer (14, 15) , is consistently associated with both improved patient outcomes and more vigorous immune responses.
In fact, we demonstrated that coordinated expression of 13 MHCII pathway genes in samples of triple negative breast cancer (TNBC) is positively associated with prolonged progression free survival and the accumulation of tumor-infiltrating lymphocytes (TILs) (14) . Even more strikingly, the expression of the class II transcriptional activator (CIITA), the master regulator of MHCII expression (16) , is independently associated with progression free survival (14) . These data suggest that the ability of tumor cells to present antigen to CD4+ T cells is a critical component of functional anti-tumor immune responses.
Unlike CD8+ T cells, CD4+ T cells are typically not cytolytic, but instead make cytokines that promote inflammation and cellular activation. Moreover, CD4+ T cells provide "help" to CD8+ T cells by promoting dendritic cell activation and cross-presentation (17, 18) . T cells responding to persistent antigens, such as those expressed during chronic infections or by tumor cells, often become exhausted (21) . Exhausted T cells are unable to express cytokines or kill target cells (22) , a phenotype that allows tumor outgrowth despite initial immune activation. T cell exhaustion is caused by chronic TCR stimulation, often in the absence of costimulation or cytokines (21) . For example, CD8+ T cells that fail to receive help from CD4+ T cells acquire a "helpless" or exhausted phenotype (23, 24) . Inhibitory receptors on T cells, such as PD-1, also contribute to T cell exhaustion (25) , particularly when their ligands are expressed on target cells, such as tumor cells.
Interestingly, PD-1 blockade is more successful in melanoma patients whose tumors also express MHCII (8) . Thus, MHCII expression on tumor cells may promote successful anti-tumor immunity by enhancing CD4+ helper functions and preventing the exhaustion of CD8+ T cells or allowing exhausted T cells to recover when inhibitory molecules are blocked.
Here we tested how ectopic expression of MHCII on murine TS/A breast tumor cells altered tumor-specific CD4+ and CD8+ T cell responses. We found that local MHCII expression increased the magnitude and duration of both CD4+ and CD8+ T cell responses in tumors. We also observed alterations in the T cell repertoire, with more clonotypes expanded to a larger extent in MHCII-expressing tumors. Interestingly, although effector functions of T cells were significantly augmented and prolonged in MHCII-expressing tumors, both CD4+ and CD8+ T cells eventually became exhausted.
Moreover, while more CD8+ T cells in MHCII-expressing tumors expressed PD-1 and higher amounts thereof, the blockade of PD-1 did not reverse the exhausted phenotype of either CD4+ or CD8+ T cells or impact tumor growth. These data suggest that MHCII expression on tumor cells expands the T cell repertoire and delays, but does not prevent, T cell exhaustion, which temporarily abates tumor growth. However, additional suppressive mechanisms must be overcome to achieve tumor eradication.
MATERIALS and METHODS

Cell culture, transfection, and selection
The TS/A murine mammary adenocarcinoma cell line was generously provided by Dr. 
RNA isolation and nanostring analysis
Total RNA was purified from excised tumors using the RNeasy Mini kit (Qiagen) and quantified by optical density at 260 nm using a DeNovix DS-11 spectrophotometer (DeNovix Inc.). Total RNA from blood was obtained from ∼1 mL (from mouse cardiac puncture) of whole blood collected into Paxgene RNA tubes using the Paxgene blood RNA kit (Qiagen) according to manufacturer instructions. The quality of RNA was assessed using Bioanalyzer 2100 (Agilent) and final concentration determined by Qubit (Life Technologies).
For nanostring analysis, 100 ng of purified RNA was added to 3 µL of Reporter CodeSet and 2 µL Capture ProbeSet in accordance with manufacturer's recommendations (NanoString Technologies), and hybridized at 65°C overnight. Samples were processed the following day using the nCounter DxPrep Station and nCounter Dx Digital Analyzer (NanoString Technologies). Consumables were provided as an nCounter master kit by the manufacturer (NanoString Technologies). Data was normalized to housekeeping genes and analyzed using the nSolver 2.6 software. Heat maps were created using Cluster 3.0 and Java TreeView-1.1.6r4.
Mice, tumor administration and antibody treatments
BALB/c mice of at least 6 weeks of age were purchased from Charles River Laboratories 
Tumor disassociation and T cell restimulation
Tumors were excised, weighed using an AL54 analytical balance (Mettler Toledo), and diced using a scalpel. Tumor fragments were then incubated in 2 mL RPMI1640 media (Lonza) supplemented with 5% FBS, 1.25 mg collagenase (c7657, Sigma) and 150 U DNase (d5025, Sigma), followed by gentle shaking at 200 rpm for 35 minutes at 37°C.
Cell suspensions were filtered through 70 µm nylon cell strainers (Corning) and used for flow cytometry or T cell restimulation. For T cell stimulation, cells were washed and resuspended in RPMI1640, 5% FBS, 5 ng/mL phorbol 12-myristate 13-acetate (Sigma), 65 ng/mL ionomycin (ThermoFisher Scientific), and 10 µg/mL brefeldin A (Sigma) and cultured at 37°C for 5 hours.
Flow cytometry and antibodies
Cell cycle analysis was performed by releasing non-confluent TS/A and TS/A-hCIITA cells from culture dishes using Accutase with 0. Samples were run on a BDFACS Canto II system (BD Biosciences) data was analyzed using FlowJo version 9.9.
T cell repertoire sequencing and analysis
For TCR library preparation, we used the commercially available iRepertoire platform (iRepertoire, Huntsville, AL) for nested amplicon arm-PCR of the CDR3 of the mouse TCR β-chains and addition of adaptors for Illumina platform sequencing. Reverse transcription of 300 to 500 ng of RNA was conducted with a One-Step reverse transcription and amplification kit (Qiagen) according to the manufacturer's protocol. The PCR product was purified using Ampure XP magnetic beads (Agencourt), and secondary amplification of the resulting product was performed (TopTaq PCR Kit, Qiagen), allowing addition of Illumina adapter sequences (manufacturer's protocol).
Libraries were purified with Ampure XP magnetic beads and sequenced using Illumina MiSeq 150 nt paired-end read-length. The TCR CDR3 sequences were extracted from the raw sequencing data by iRepertoire. Briefly, raw paired-end fastq files were first demultiplexed based on the internal 6-nt barcode sequences added during library construction. The merged reads were mapped using a Smith-Waterman algorithm to germline V, D, J and C reference sequences downloaded from the IMGT web site (http://www.imgt.org). To define the CDR3 region, the position of CDR3 boundaries of reference sequences from the IMGT database were migrated onto reads through mapping results and the resulting CDR3 regions were extracted and translated into amino acids . Reading frames amino acid motif that was uninterrupted by a stop codon were identified as productive CDR3 amino acid sequences. Reads were filtered and error-corrected using iRepertoire proprietary SMART algorithm.
Statistical Analysis
Hypothesis of difference testing between pooled replicate group means at each time point was done using multiple, unpaired independent t-tests with the Holm-Sidak method and assuming α=0.05. Statistical analyses were calculated using GraphPad Prism version 7.0a and all reported p-values are two-tailed. The TCR high-throughput sequencing data were analyzed in R environment using tcR package and common R routines. Diversity was measured using D50 immune repertoire diversity index. CDR3
sequence similarity between repertoires was assessed using overlap index and weighted Horn's index available in the tcR package.
RESULTS
Transfection with hCIITA promotes MHCII expression on TS/A breast cancer cells
Our previous studies show that patients whose triple negative breast tumors expressed MHCII have greater numbers of tumor infiltrating lymphocytes (TILs) and experience prolonged progression free survival relative to those lacking MHCII expression (14) .
Given found that hCIITA-transfected cells also expressed high levels of murine MHCII on the cell surface ( Figure 1B ). To assess whether hCIITA expression altered cellular proliferation, we used propidium iodide to measure DNA content and found that the cell cycling times of hCIITA-expressing and control TS/A cells were nearly equivalent ( Figure   1C ). These data demonstrate that hCIITA promotes the expression of genes in the MHCII pathway and drives murine MHCII expression on the cell surface of TS/A breast cancer cells.
Surface expression of MHCII impairs tumor growth in vivo
To test whether MHCII expression was maintained on CIITA-transfected TS/A cells in To better understand how expression of the MHCII pathway in tumor cells impacted the local microenvironment, we excised whole tumors from recipient BALB/c mice on days 10, 14, 17, and 21, prepared mRNA and analyzed the expression of a panel of 48 genes using a NanoString assay. As expected, we found that reads of mRNAs encoding MHCII α and β chains were more numerous in TS/A-hCIITA tumors relative to control tumors across time points (Figure 2E ), whereas reads of mRNAs encoding MHC class I molecules were largely similar. We also observed that several mediators of immunity and cytotoxicity -IFNγ, granzyme B and perforin -were upregulated in TS/A-hCIITA tumors relative to control tumors ( Figure 2E ). Interestingly, we found that the master transcription factor for regulatory T cells, FoxP3 , was expressed similarly in TS/AhCIITA and control tumors. In contrast, we found that the expression of other genes, such as HIF-1a, a transcription factor that facilitates tumor cell survival in hypoxic conditions (26) and promotes the ability of tumor-associated macrophages to suppress T cells (27) , was consistently reduced in TS/A-hCIITA tumors. Together, these data demonstrated that MHCII expression on TS/A tumors promoted adaptive immune responses, altered the tumor microenvironment, and impaired tumor growth.
MHCII-expressing tumors have increased CD4+ T cell infiltration and activation
Given that MHCII molecules stimulate CD4+ T cells, we hypothesized that MHCII- 
Expression of MHCII expands the responding T cell clones in tumors
The increased numbers of activated CD4+ and CD8+ T cells in MHCII-expressing tumors raised the possibilities that particular clones of T cells were expanding to a greater degree or that a broader array of T cell clones were being recruited to the tumor site. To test these possibilities, we harvested whole tumor and matched blood samples from three animals in each group on days 10, 14, 17, and 21 and sequenced the CDR3 region of the TCRβ chain to identify unique T cell clones. We first assessed the number of unique CDR3 reads in each sample, and found that estimated size of the TCRβ repertoire in the tumor was significantly smaller than that in peripheral blood ( Figure 7A ). Importantly, there was no difference in mean repertoire sizes between groups ( Figure 7A ), demonstrating that we have sufficient sequencing depth in each sample to appropriately compare them. We next compared the relative proportions of individual clones in each sample and found a relatively uniform distribution of (mostly infrequent) clones in blood, but found many examples of dramatically expanded clones in tumor samples ( Figure 7B ). Moreover, we observed more expanded clones and a greater magnitude thereof in TS/A-hCIITA tumors than in control tumors, whereas no differences were observed between blood samples from these same mice ( Figure 7B ).
We quantified these results using the D50 repertoire diversity index of each cohort. We found that blood samples had high D50 scores that were not significantly different between TS/A-hCIITA and control tumor bearing mice, whereas tumor samples had low D50 scores and MHCII-expressing tumors were significantly lower than control tumors ( Figure 7C ). This result can be attributed to the local accumulation of the most abundant clonotypes, especially of the top 10 clones (data not shown). These data suggested that expanded T cell clones accumulated in tumors, but were minimally evident in the blood.
We next tested whether clonotypes of identical amino acid sequence were expanded in multiple mice, possibly because of dominant T cell responses to particular tumor antigens. By performing pairwise comparisons of normalized numbers of shared amino acid sequences, we found increased sharing of CDR3 sequences between TILs within MHCII-expressing tumors ( Figure 7D ). In addition, overlap indexes showed a significantly greater number of common sequences in TS/A-hCIITA tumors relative to controls ( Figure 7E ). Moreover, weighting sequence overlap by shared clones' abundance using Horn's pairwise overlap index also yielded a significant difference ( Figure 7F ). Finally, comparing sequences common to multiple mice (rather than two in pairwise comparison) revealed a significant increase in the number of shared sequences amongst TILs from MHCII-expressing tumors ( Figure 7G ). Collectively, these data suggested that MHCII expression on TS/A-hCIITA tumors increased intratumoral T cell clonal expansion, including clonotypes shared between mice, suggesting that they are responding to particular tumor antigens. 
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